Immediate Impact

64 standout
Sub-graph 1 of 19

Citing Papers

Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial
2024 Standout
Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial
2024 Standout
1 intermediate paper

Works of Ilan Yanuv being referenced

Cardiorenal outcomes with dapagliflozin by baseline glucose‐lowering agents: Post hoc analyses from DECLARE‐TIMI 58
2020

Author Peers

Author Last Decade Papers Cites
Ilan Yanuv 637 200 261 25 718
Aliza Rozenberg 637 200 262 26 719
Gary K. Yang 362 149 351 28 618
Amanda Mather 492 267 262 22 786
Ryo Kodera 360 169 185 16 632
Xiaoni Liu 579 314 346 19 764
Daniel Lorber 395 125 158 24 765
Herbert Gershberg 379 154 108 40 774
Fotini Adamidou 393 92 202 29 618
Joaquim Calado 446 445 313 30 798
Norm Rosenthal 616 362 283 19 769

All Works

Loading papers...

Rankless by CCL
2026